InMed Pharmaceuticals (INM) Liabilities from Discontinued Operations (2025 - 2026)
InMed Pharmaceuticals (INM) reported Liabilities from Discontinued Operations of 810334.0 for Q1 2026, up 367.22% quarter-over-quarter from 173438.0 in Q2 2025.
InMed Pharmaceuticals (INM) Liabilities from Discontinued Operations (2025 - 2026) Analysis & Trends
InMed Pharmaceuticals has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 810334.0 in Q1 2026.
- For the quarter ending Q1 2026, Liabilities from Discontinued Operations changed N/A year-over-year to 810334.0; the trailing twelve-month figure through Mar 2026 stood at 810334.0 (changed N/A YoY), and the FY2025 full-year result was 173438.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q1 2026 stood at 810334.0, up from 173438.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 810334.0 in Q1 2026, with the low at 173438.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | InMed Pharmaceuticals | 6.00 Mn | 756,271.05 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 810,334.00 |
| Mar 31, 2026 | 810,334.00 |
| Jun 30, 2025 | 173,438.00 |
| Jun 30, 2025 | 173,438.00 |